Dec 19 - U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, and the company said the drug would cost $83,319 for a typical 12-week plan, a bit below its huge selling competitor Solvadi from Gilead Sciences.
* Ebola death toll nears 7,000 (Recasts after Sierra Leone visit)
Dec 19 - An AbbVie Inc spokeswoman on Friday said that the company's newly approved hepatitis C treatment will cost $83,319 for a 12-week course, coming in a bit below the price of competing treatments from Gilead Sciences Inc.
CHICAGO, Dec 19 - A child who arrived in Chicago with a fever was under observation on Friday at a city hospital to rule out the Ebola virus, hospital officials said.
Dec 19 - Cubist Pharmaceutical Inc's drug to treat complicated urinary tract and intra-abdominal infections won U.S. approval on Friday, highlighting the regulator's interest in tackling the growing threat of the so-called superbugs.
No related earnings announcements are currently scheduled within the next 7 days.